BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35691590)

  • 1. Whole-genome and transcriptome analysis enhances precision cancer treatment options.
    Pleasance E; Bohm A; Williamson LM; Nelson JMT; Shen Y; Bonakdar M; Titmuss E; Csizmok V; Wee K; Hosseinzadeh S; Grisdale CJ; Reisle C; Taylor GA; Lewis E; Jones MR; Bleile D; Sadeghi S; Zhang W; Davies A; Pellegrini B; Wong T; Bowlby R; Chan SK; Mungall KL; Chuah E; Mungall AJ; Moore RA; Zhao Y; Deol B; Fisic A; Fok A; Regier DA; Weymann D; Schaeffer DF; Young S; Yip S; Schrader K; Levasseur N; Taylor SK; Feng X; Tinker A; Savage KJ; Chia S; Gelmon K; Sun S; Lim H; Renouf DJ; Jones SJM; Marra MA; Laskin J
    Ann Oncol; 2022 Sep; 33(9):939-949. PubMed ID: 35691590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care.
    Weymann D; Laskin J; Jones SJM; Roscoe R; Lim HJ; Renouf DJ; Schrader KA; Sun S; Yip S; Marra MA; Regier DA
    J Community Genet; 2022 Oct; 13(5):523-538. PubMed ID: 34843087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching methods in precision oncology: An introduction and illustrative example.
    Weymann D; Laskin J; Jones SJM; Lim H; Renouf DJ; Roscoe R; Schrader KA; Sun S; Yip S; Marra MA; Regier DA
    Mol Genet Genomic Med; 2021 Jan; 9(1):e1554. PubMed ID: 33237632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of whole genome and transcriptome analysis (WGTA) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies.
    Tessier-Cloutier B; Grewal JK; Jones MR; Pleasance E; Shen Y; Cai E; Dunham C; Hoang L; Horst B; Huntsman DG; Ionescu D; Karnezis AN; Lee AF; Lee CH; Lee TH; Twa DD; Mungall AJ; Mungall K; Naso JR; Ng T; Schaeffer DF; Sheffield BS; Skinnider B; Smith T; Williamson L; Zhong E; Regier DA; Laskin J; Marra MA; Gilks CB; Jones SJ; Yip S
    J Pathol Clin Res; 2022 Jul; 8(4):395-407. PubMed ID: 35257510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.
    Lavoie JM; Mitchell T; Lee SE; Deol B; Chia SK; Gelmon KA; Kollmannsberger CK; Tinker AV; Jones SJM; Marra M; Laskin J; Renouf DJ
    Invest New Drugs; 2020 Oct; 38(5):1601-1604. PubMed ID: 31907737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers.
    Deyell RJ; Shen Y; Titmuss E; Dixon K; Williamson LM; Pleasance E; Nelson JMT; Abbasi S; Krzywinski M; Armstrong L; Bonakdar M; Ch'ng C; Chuah E; Dunham C; Fok A; Jones M; Lee AF; Ma Y; Moore RA; Mungall AJ; Mungall KL; Rogers PC; Schrader KA; Virani A; Wee K; Young SS; Zhao Y; Jones SJM; Laskin J; Marra MA; Rassekh SR
    Nat Commun; 2024 May; 15(1):4165. PubMed ID: 38755180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.
    Jobanputra V; Wrzeszczynski KO; Buttner R; Caldas C; Cuppen E; Grimmond S; Haferlach T; Mullighan C; Schuh A; Elemento O
    Semin Cancer Biol; 2022 Sep; 84():23-31. PubMed ID: 34256129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
    Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
    Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
    Pender A; Titmuss E; Pleasance ED; Fan KY; Pearson H; Brown SD; Grisdale CJ; Topham JT; Shen Y; Bonakdar M; Taylor GA; Williamson LM; Mungall KL; Chuah E; Mungall AJ; Moore RA; Lavoie JM; Yip S; Lim H; Renouf DJ; Sun S; Holt RA; Jones SJM; Marra MA; Laskin J
    Clin Cancer Res; 2021 Jan; 27(1):202-212. PubMed ID: 33020056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making.
    Chahal M; Pleasance E; Grewal J; Zhao E; Ng T; Chapman E; Jones MR; Shen Y; Mungall KL; Bonakdar M; Taylor GA; Ma Y; Mungall AJ; Moore RA; Lim H; Renouf D; Yip S; Jones SJM; Marra MA; Laskin J
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.
    Xu C; Nikolova O; Basom RS; Mitchell RM; Shaw R; Moser RD; Park H; Gurley KE; Kao MC; Green CL; Schaub FX; Diaz RL; Swan HA; Jang IS; Guinney J; Gadi VK; Margolin AA; Grandori C; Kemp CJ; Méndez E
    Clin Cancer Res; 2018 Jun; 24(12):2828-2843. PubMed ID: 29599409
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
    Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
    BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decision support framework for genomically informed investigational cancer therapy.
    Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.
    Titmuss E; Milne K; Jones MR; Ng T; Topham JT; Brown SD; Schaeffer DF; Kalloger S; Wilson D; Corbett RD; Williamson LM; Mungall K; Mungall AJ; Holt RA; Nelson BH; Jones SJM; Laskin J; Lim HJ; Marra MA
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
    Tuxen IV; Rohrberg KS; Oestrup O; Ahlborn LB; Schmidt AY; Spanggaard I; Hasselby JP; Santoni-Rugiu E; Yde CW; Mau-Sørensen M; Nielsen FC; Lassen U
    Clin Cancer Res; 2019 Feb; 25(4):1239-1247. PubMed ID: 30274980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.
    Van Allen EM; Robinson D; Morrissey C; Pritchard C; Imamovic A; Carter S; Rosenberg M; McKenna A; Wu YM; Cao X; Chinnaiyan A; Garraway L; Nelson PS
    Oncotarget; 2016 Aug; 7(33):52888-52899. PubMed ID: 27167109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Precision Medicine: Why More Is More and DNA Is Not Enough.
    Schütte M; Ogilvie LA; Rieke DT; Lange BMH; Yaspo ML; Lehrach H
    Public Health Genomics; 2017; 20(2):70-80. PubMed ID: 28595192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
    Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
    Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
    Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
    World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.